ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a partnership with the California Medical Innovations Institute (CALMI2), a non-profit organization exclusively for research, scientific and innovation purposes led by its founder, Dr Ghassan Kassab.
"Our collective vision is to bring together physical and life science researchers, clinicians, engineers, and computational scientists to address the significant health care challenges such as posed in the field of Regenerative Medicine," said Dr Kassab in a statement.
Dr Kassab's group has obtained nearly $100 million worth of extramural research grants to fund scientific medical developments, including internal programs and collaborations with the life science industry helping bring solutions from bench to bedside.
"We are honored to work with Dr Kassab and the CALMI2 team to ensure the research we help sponsor is designed and completed with diligence and care and leads to solutions for high unmet medical needs," said ChitogenX CEO Philippe Deschamps.
READ: ChitogenX to create new near-term revenue by selling medical grade chitosan
The company said the first focus of the partnership will evaluate whether ChitogenX lyophilised chitosan matrix, combined with platelet rich plasma or other biologics can improve healing of a range of tissues germane to common surgical practice.
For instance, resection of the human pancreas as is done for various tumors, is often compromised by leakage of damaging enzymes that lead to a stormy, and expensive post-operative course. The concept of using ChitogenX proprietary solution to address this problem would be clinically and economically meaningful, the company said.
CalMI2 was formed in July 2014, and the basic premise for its foundation was that an institute that functions as an "innovation engine" in collaboration with clinicians and industry will be very effective at clinical translation. Specifically, CalMI2 is dedicated to conducting basic and applied research to advance translation of diagnostics and therapeutics for the improvement of human health.
The Institute brings together physical and life science researchers, clinicians, engineers, and computational scientists to address the significant health care challenges of heart and vascular disease, gastrointestinal, obesity, and metabolic disorders through a multi-scale understanding of organ systems.
ChitogenX is a clinical-stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing.
Contact the author at jon.hopkins@proactiveinvestors.com